Supplementation

Of 7,592 urban working Indians who answered the supplement question in WHI 2026, 66.2% take nothing. Vitamin D, the most common single supplement, reaches 20.4%. No other supplement clears 16%. This is a low-supplementation population — and the more important finding is that the deficiencies the blood panels record are nearly universal. In the same broad audience, 81.4% of Vitamin D readings sit below the insufficiency threshold and 69.6% of B12 readings fall under 300 pg/mL (see Vitamin D and Vitamin B12 risk pages). The people most likely to need a supplement are not the people taking one.

The question was multi-select, so the shares are independent and do not sum. A respondent taking Vitamin D and B12 is counted in both rows. Brand, dose, and frequency are not captured — the survey records that a person takes Vitamin D, not whether they take enough of it, in a form the body can use, with the food it needs to be absorbed. That distinction is where most of the deficiency hides.

The supplementation gap: 20.4% take Vitamin D, 81.4% are deficient in it#

The cleanest way to read this page is to put the survey number next to the biomarker number for the same nutrient.

For Vitamin D, 60.1% of readings are not merely insufficient but severely deficient (<20 ng/mL). The supplement that would address it reaches one in five. The two numbers are measured on the same broad audience in the same year, and the rows are not linked at the individual level — so this is an audience-level mismatch, not a claim that the specific people testing low are the specific people skipping the pill. But the direction is unambiguous. The need is near-universal; the response is sparse.

Vitamin D uptake fell while the deficiency held#

Vitamin D supplementation dropped almost six points year on year, on a survey sample roughly 2.6× the size. B12 held flat. The drop matters because Vitamin D is the supplement the biomarker data most clearly justifies — 81.4% of the audience is insufficient — and it is the one moving in the wrong direction. The 2026 sample is larger and broader than the 2025 one, which over-indexed on metro, higher-income respondents; part of the fall is that the wider sample reaches further into the lower-uptake cohorts. But the headline is intact: in the year just measured, fewer urban professionals supplemented the deficiency that defines them.

Women supplement more than men, and the gap widens with age#

Women are more than 12 percentage points more likely than men to take any supplement, and 1.7× as likely to take Vitamin D specifically. The gap is consistent across every supplement that addresses a documented deficiency — Vitamin D, B12, multivitamins, magnesium — and reverses only on creatine, which men take more of. The pattern is the familiar one in health behaviour: women engage earlier and more consistently with preventive routines, including the ones tied to bone health, where the deficiency burden compounds toward menopause.

The age cut sharpens it. Female uptake climbs steeply with age; male uptake stays flat.

A woman in her 50s is more than twice as likely to supplement as a man the same age, and roughly twice as likely as a woman in her 20s. Men supplement at about 30% regardless of decade — the behaviour does not respond to age, and by extension does not respond to the accumulating deficiency that age brings. The 50–59 cells are small (83 women, 145 men) and carry noise, but the gradient is consistent across the 30s and 40s, where the samples are large.

Supplement use tracks income more cleanly than it tracks deficiency#

The top income band takes supplements at roughly twice the rate of the ₹3–6 lakh band, and takes Vitamin D at 2.5× the rate. Supplementation is, in part, a function of disposable income and access — the same income-gated pattern the Income & Job Role page traces through screening and preventive behaviour, and the same gradient WHI 2025 reported. But the deficiency it is meant to address does not follow income the way the supplement does. Vitamin D insufficiency runs near-universal across the income distribution; the supplement clusters at the top. The result is a market that allocates the response by spending power rather than by need.

One wrinkle breaks the clean gradient: the lowest band, <₹3 lakh, supplements more than the two bands directly above it (34.5% vs 28.9% and 30.2%). The likeliest read is composition — this band mixes early-career employees with a slice of older, dependent respondents on the policy who supplement on medical advice — but the survey cannot separate the two cleanly. Treat the headline (top-versus-middle gradient) as solid and the very bottom of the distribution as noisier.

Creatine is the one supplement aimed at the gym, not the clinic#

Every supplement examined so far skews female and rises with age. Creatine does the opposite.

Men take creatine 2.5× as often as women; the youngest cohort takes it 5.7× as often as the oldest. It is the only supplement on the list whose use falls with age. Creatine is taken for muscle and athletic performance, not to correct a measured deficiency — the gym demographic, not the clinic demographic. It sits in the data as the marker of a separate motivation entirely: optimisation rather than correction. The population taking it is young, male, and metabolically among the least at-risk on this page. The supplements that would address the population's actual deficiencies are taken by almost everyone except them.

City and work-mode patterns are real but modest#

Supplement use varies by city, but the spread is narrow next to the gender and income gaps. Delhi NCR leads at 42.2% taking any supplement; Chennai and Hyderabad trail near 29%. The notable point is what didn't replicate: Bengaluru led every city on supplement use in WHI 2025 (52.1%) and sits mid-pack in 2026 (33.2%) — a reminder that the 2025 city rankings rode a smaller, less representative sample and should not be read as a stable trend.

Work mode shows a clean three-point spread: home-workers supplement most (39.6%), office-workers least (31.5%), hybrid in between. The likeliest explanation is that work mode is partly a proxy for income and seniority — WFH skews toward higher-paid knowledge roles — rather than an independent effect of where the laptop sits.